-
Intracellular L-PGDS-Derived 15d-PGJ2 Inhibits CaMKII Through Lipoxidation to Alleviate Cardiac Ischemia/Reperfusion Injury. Circulation (IF 35.5) Pub Date : 2025-05-21 Qingmei Hu,Junxia Zhang,Xile Luo,Peiyu Hu,Jiayi Li,Fan Li,Zeyuan Wang,Shuyang Zhang,Zishan Jiao,Yitong Liu,Jiaxin Duanmu,Li Jin,Peng Xie,Wenneng Zhu,Wen Zheng,Haibao Shang,Xinli Hu,Zhixing Chen,Rui-Ping Xiao,Yan Zhang
BACKGROUND Myocardial ischemia/reperfusion (I/R) injury is a substantial challenge to the management of ischemic heart disease, the leading cause of mortality worldwide. Arachidonic acid (AA) is a prominent polyunsaturated fatty acid in the human body and plays an important role in various physiological and pathological conditions. AA metabolic enzymes determine AA levels; however, currently there
-
Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. Circulation (IF 35.5) Pub Date : 2025-05-20 Albert Wiegman,Amy L Peterson,Robert A Hegele,Eric Bruckert,Anja Schweizer,Anastasia Lesogor,Yibo Wang,Joep Defesche
BACKGROUND Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for cardiovascular risk reduction; however, many patients do not reach LDL-C treatment goals. Inclisiran, a
-
Partial Heart Transplantation: Early Experience With Pediatric Heart Valve Replacements That Grow. Circulation (IF 35.5) Pub Date : 2025-05-19 Neel K Prabhu,Berk Aykut,Michael Mensah-Mamfo,Douglas M Overbey,Joseph W Turek
Heart valve replacement in children is fraught with long-term morbidity and mortality rates, largely because conventional implants lack the capacity to grow with the child. Partial heart transplantation presents a potential solution by transplanting only specific segments of a donor heart, thereby providing a living and growing heart valve implant. This approach harnesses the full spectrum of cardiac
-
Leveraging Transcriptional Readouts as a Platform for Drug Repurposing in Cardiomyopathy. Circulation (IF 35.5) Pub Date : 2025-05-19 Ahmed I Mahmoud,Hesham A Sadek
-
Response by Bulluck and Hausenloy to Letter Regarding Article, "Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (the PITRI Trial)". Circulation (IF 35.5) Pub Date : 2025-05-19 Heerajnarain Bulluck,Derek J Hausenloy,
-
Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand? Circulation (IF 35.5) Pub Date : 2025-05-19 Siddharth M Patel,Robert P Giugliano,Christian T Ruff
-
Letter by Berry and McCartney Regarding Article, "Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (The PITRI Trial)". Circulation (IF 35.5) Pub Date : 2025-05-19 Colin Berry,Peter McCartney
-
Diagnostic Yield and Outcomes of Incidental Thoracic Aortic Dilatation in the National Health Service Targeted Lung Health Check Program: Novel Insights from a Regional Tertiary Center in the United Kingdom. Circulation (IF 35.5) Pub Date : 2025-05-19 Dalia Ahmed,Nehan Khalid,Vivek Shrivastava,Claudette Philips,Kanwal Tariq,Imran Sunderji,Oliver Byass,Raghav T Bhatia
-
Genomic Editing of a Pathogenic Mutation in ACTA2 Rescues Multisystemic Smooth Muscle Dysfunction Syndrome in Mice. Circulation (IF 35.5) Pub Date : 2025-05-16 Qianqian Ding,Peiheng Gan,Zhisheng Xu,Hui Li,Lei Guo,Camryn MacDonald,Wei Tan,Efrain Sanchez-Ortiz,John R McAnally,Yu Zhang,Dileep Karri,Lin Xu,Ning Liu,Eric N Olson
Background: Vascular smooth muscle cells (vSMCs), the predominant cell type in the aortic wall, play a crucial role in maintaining aortic integrity, blood pressure, and cardiovascular function. vSMC contractility and function depend on smooth muscle alpha-actin 2 (ACTA2). The pathogenic variant ACTA2 c.536G>A (p. R179H) causes multisystemic smooth muscle dysfunction syndrome (MSMDS), a severe disorder
-
Palliative and End-of-Life Care During Critical Cardiovascular Illness: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-05-15 Erin A Bohula,Michael J Landzberg,Venu Menon,Carlos L Alviar,Gregory W Barsness,Daniela R Crousillat,Nelia Jain,Robert Page,Rachel Wells,Abdulla A Damluji,
Cardiac intensive care units are witnessing a demographic shift, characterized by patients with increasingly complex or end-stage cardiovascular disease with a greater burden of concomitant comorbid noncardiovascular disease. Despite technical advances in care that may be offered, many critically ill cardiovascular patients will nevertheless experience significant morbidity and mortality during the
-
Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-05-13 Wenzhu Li,Suresh Vedantham,Farouc A Jaffer,Stavros K Kakkos,Jean-Philippe Galanaud,Paul P Dobesh,Eri Fukaya,Mary O Whipple,Olamide Alabi,Rachel P Rosovsky,Peter K Henke,
The "open vein hypothesis" postulates that early thrombus clearance and restoration of venous blood flow may prevent postthrombotic syndrome after proximal deep vein thrombosis. Since its proposal several decades ago, new insights from basic and clinical studies have motivated a re-evaluation and refinement of this hypothesis. According to data from these studies, susceptibility to postthrombotic syndrome
-
METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy. Circulation (IF 35.5) Pub Date : 2025-05-13 Chunyan Wang,Siman Shen,Jiayi Kang,Aya Sugai-Munson,Xiao Xiao,Yajing Zhang,Junyuan Zhu,Zipeng Liu,Tina B McKay,Oluwaseun Akeju,Eric R Jonas,Amrut V Ambarar,Michael R Bristow,Weifeng Yao,Haobo Li
BACKGROUND Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism underlying cardiac benefits of exercise in DiaCM remains incompletely understood. N6-methyladenosine (m6A) is the most common form of messenger RNA modification in eukaryotes and has been implicated in cardiac development and disease. However, the role of m6A in DiaCM and in the
-
Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure. Circulation (IF 35.5) Pub Date : 2025-05-13 Yitian Zheng,Yueyue Cao,Wenyao Wang,Yicheng Tong,Shuaixing Wang,Chen Li,Mingming Zhao,Yao Song,Yuan-Geng-Shuo Wang,Jiating Qi,Chao Wu,Jie Yang,Jilin Zheng,Jun Gao,Jingjia Wang,Qing Yang,Gang Liu,Jiajun Zhao,Yan Zhang,Han Xiao,You-Yi Zhang,Yi-Da Tang
BACKGROUND Hypothyroidism leads to multiple organ dysfunction, with the heart the most affected. However, the pathologic mechanism of hypothyroidism-induced heart failure remains to be completely elucidated. Thyroid hormone replacement therapy enhances myocardium systolic function but increases the occurrence of arrythmias. There is an urgent need to explore these mechanisms in detail and to discover
-
Response by Reitan et al to Letter Regarding Article, "Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study". Circulation (IF 35.5) Pub Date : 2025-05-12 Christian Reitan,Pontus Andell,Robin Hofmann,Tomas Jernberg
-
Cell Type-Level Epigenetics at the Frontier of Atherosclerosis Research. Circulation (IF 35.5) Pub Date : 2025-05-12 Anthony S Zannas
-
Letter by Zhang et al Regarding Article, "Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study". Circulation (IF 35.5) Pub Date : 2025-05-12 Zhiqiang Zhang,Xinyue Yang,Zhiyi Zhang
-
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4. Circulation (IF 35.5) Pub Date : 2025-05-12 Naveed Sattar,Govinda J Weerakkody,Darren K McGuire,Mikhail N Kosiborod,Matthew M Y Lee,Paul Welsh,Ewan R Pearson,Russell J Wiese,Kevin Duffin,Jonathan Wilson,Noemi Pavo,Martin Hülsmann,Imre Pavo
-
Does Coronary Calcium Mean the Same in Active and Sedentary Individuals? Circulation (IF 35.5) Pub Date : 2025-05-05 Paul D Thompson
-
Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions. Circulation (IF 35.5) Pub Date : 2025-05-05 Marco Metra,Daniela Tomasoni,Marianna Adamo,Stefan D Anker,Antoni Bayes-Genis,Ralph Stephan von Bardeleben,Michael Böhm,Erwan Donal,Gerasimos S Filippatos,Francesco Maisano,Piotr Ponikowski,Gianluigi Savarese,Fabien Praz,Javed Butler
Mitral regurgitation and tricuspid regurgitation are the most common valvular heart diseases in patients with heart failure and have independent prognostic value. Transcatheter interventions are now available for the treatment of valvular heart disease, and their efficacy and safety have been tested in randomized controlled trials. However, evidence is still limited and sometimes inconclusive because
-
Letter by Gu et al Regarding Article, "Antisense Oligonucleotide Therapy for Calmodulinopathy". Circulation (IF 35.5) Pub Date : 2025-05-05 Siyuan Gu,Ye Chen,Xiaojian Shi
-
Response by Bortolin and Pu to Letter Regarding Article, "Antisense Oligonucleotide Therapy for Calmodulinopathy". Circulation (IF 35.5) Pub Date : 2025-05-05 Raul H Bortolin,William T Pu
-
Causal Relevance of Lp(a) for Coronary Heart Disease and Stroke Types in East Asian and European Ancestry Populations: A Mendelian Randomization Study. Circulation (IF 35.5) Pub Date : 2025-04-29 Robert Clarke,Neil Wright,Kuang Lin,Canqing Yu,Robin G Walters,Jun Lv,Michael Hill,Christiana Kartsonaki,Iona Y Millwood,Derrick A Bennett,Daniel Avery,Ling Yang,Yiping Chen,Huaidong Du,Paul Sherliker,Xiaoming Yang,Dianjianyi Sun,Liming Li,Chan Qu,Santica Marcovina,Rory Collins,Zhengming Chen,Sarah Parish,
BACKGROUND Elevated plasma levels of Lp(a) [lipoprotein(a)] are a causal risk factor for coronary heart disease and stroke in European individuals, but the causal relevance of Lp(a) for different stroke types and in East Asian individuals with different Lp(a) genetic architecture is uncertain. METHODS We measured plasma levels of Lp(a) in a nested case-control study of 18 174 adults (mean [SD] age
-
A Plea for a Genetics-First Approach in Arrhythmogenic Cardiomyopathies. Circulation (IF 35.5) Pub Date : 2025-04-28 Anneline S J M Te Riele,J Peter van Tintelen,Richard N W Hauer
-
New Tools for Precision Targeting of Origin-Specific Vascular Smooth Muscle Cells Using Intersectional Genetics. Circulation (IF 35.5) Pub Date : 2025-04-28 Mark W Majesky
-
Interplay Between Epicardial Adipose Tissue and Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. Circulation (IF 35.5) Pub Date : 2025-04-28 Shiro Nakamori,Taku Omori,Naoki Fujimoto,Masaki Ishida,Yasutaka Ichikawa,Kakuya Kitagawa,Hajime Sakuma,Kaoru Dohi
-
Letter by Dong et al Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation". Circulation (IF 35.5) Pub Date : 2025-04-28 Jiayang Dong,Xinyue Yang,Wenjuan Zhang
-
Response by Bonnesen et al to Letter Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation". Circulation (IF 35.5) Pub Date : 2025-04-28 Kasper Bonnesen,Uffe Heide-Jørgensen,Morten Schmidt
-
Suppression of the Prostaglandin I2-Type 1 Interferon Axis Induces Extramedullary Hematopoiesis to Promote Cardiac Repair After Myocardial Infarction. Circulation (IF 35.5) Pub Date : 2025-04-28 Huizhen Lv,Chenchen Wang,Zening Liu,Meixi Quan,Kan Li,Fanglin Gou,Xuelian Shi,Qian Liu,Ying Yu,Ping Zhu,Hui Cheng,Tao Cheng,Ding Ai
BACKGROUND Immune cells are closely associated with all processes of cardiac repair after myocardial infarction (MI), including the initiation, development, and resolution of inflammation. Spleen extramedullary hematopoiesis (EMH) serves as a crucial source of emergency mature blood cells that are generated through the self-renewal and differentiation of hematopoietic stem/progenitor cells (HSPCs)
-
COnventional vs. Optimized PERiprocedural Analgosedation vs. Total IntraVEnous Anesthesia for Pulsed-Field Ablation: a Three-Arm Randomized Controlled Trial (COOPERATIVE-PFA). Circulation (IF 35.5) Pub Date : 2025-04-27 Veronika Sochorová,Veronika Kunštátová,Pavel OsmanČík,František Duška,Dalibor Heřman,Petr Waldauf,Lukáš Povišer,Jakub Karch,Lucie Znojilová,Věra Filipcová,Jana Hozmanová,Jana Veselá,Marek Hozman
BACKGROUND Deep analgosedation (DAS) or general anesthesia (GA) is mandatory for pulsed-field ablation (PFA) of atrial fibrillation (AF). In contrast to DAS, GA (conventional or total intravenous anesthesia [TIVA]) requires airway management. To find the optimal sedation regimen, this study compared ketamine-remimazolam DAS and propofol-opioid TIVA to propofol-opioid DAS, focusing on sedation-related
-
Stepwise Anatomical Approach to Ablation of Intramural Outflow Tract Ventricular Arrhythmias Guided by Septal Coronary Venous Mapping. Circulation (IF 35.5) Pub Date : 2025-04-26 Andres Enriquez,Haran Yogasundaram,Victor Neira,Gustavo Guandalini,Timothy Markman,Poojita Shivamurthy,Matthew Hyman,Balaram Hanumanthu,David Lin,Robert Schaller,Gregory Supple,Sanjay Dixit,Rajat Deo,Saman Nazarian,Ramanan Kumareswaran,Michael Riley,Andrew E Epstein,Vincent See,Erica Zado,David Callans,David Frankel,Francis Marchlinski,Fermin Garcia
BACKGROUND Intramural site of origin is a major cause of ablation failure of ventricular arrhythmias and the optimal strategy is unclear. This study investigated the efficacy of a stepwise ablation approach for intramural outflow tract (OT) premature ventricular complexes (PVCs) guided by mapping of the septal coronary venous system. METHODS Consecutive patients with OT PVCs were included in which
-
Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL Trial. Circulation (IF 35.5) Pub Date : 2025-04-25 Louise R A Olde Nordkamp,Jolien A de Veld,Abdul Ghani,Jürgen Kuschyk,Hendrik Bonnemeier,Kerstin Bode,Lucas V A Boersma,Anouk de Weger,Jonas S S G de Jong,Ward P J Jansen,Marco Alings,Nick Bijsterveld,Mikhael F El-Chami,Rypko Joost Beukema,Kevin Vernooy,Berit T Philbert,Petr Neuzil,Peter Nordbeck,Jurren M van Opstal,Cornelis P Allaart,David J Wright,Michael Knaut,Timothy R Betts,Zachary I Whinnett,Pier
BACKGROUND The PRAETORIAN trial investigated the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) and showed non-inferiority of the S-ICD with regard to the composite endpoint of device-related complications and inappropriate shocks (IAS) after 49.1 months. Complications associated with transvenous leads are expected to occur
-
Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous ECG Monitoring Follow-Up: ADVANTAGE AF-Phase 2. Circulation (IF 35.5) Pub Date : 2025-04-24 Vivek Y Reddy,Edward P Gerstenfeld,Boris Schmidt,Jason G Andrade,Devi Nair,Andrea Natale,Walid Saliba,Philipp Sommer,Andreas Metzner,Atul Verma,Troy Hounshell,Anish Amin,Philip Gentlesk,Stanislav Weiner,Frank A Cuoco,Jamie Kim,Mohit K Turagam,Gery Tomassoni,Chinmay Patel,Ziad Issa,Michael Shehata,Allison M Anderson,Thomas J Stoltz,Jonathan D Raybuck,Torri Schwartz,Brad S Sutton,Moussa Mansour,
BACKGROUND There is sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), where lesions beyond pulmonary vein isolation (PVI) are often placed. Additionally, no large trials have used insertable cardiac monitors (ICMs) for continuous rhythm monitoring post-ablation in PerAF patients, or after PFA in any AF population. In ADVANTAGE
-
Integrin Targeting Therapies in Pulmonary Arterial Hypertension: A Roadmap for Traversing the Translational Valley of Death? Circulation (IF 35.5) Pub Date : 2025-04-21 Vineet Agrawal,Anna R Hemnes
-
Left Bundle Branch Pacing: State of the Art and Future Directions. Circulation (IF 35.5) Pub Date : 2025-04-21 Weijian Huang
-
Letter by Xu et al Regarding Article, "Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial". Circulation (IF 35.5) Pub Date : 2025-04-21 Xiaoqun Xu,Houyong Zhu,Long Cai
-
The Mechanism of Unequal RR Interval During Tachycardia. Circulation (IF 35.5) Pub Date : 2025-04-21 Jing-Jing Han,Cheng Jiang,Peng Chang
-
Cell Painting and Machine Learning Distinguish Fibroblasts From Nonfailing and Failing Human Hearts. Circulation (IF 35.5) Pub Date : 2025-04-21 Joshua G Travers,Jenna Tomkinson,Marcello Rubino,Marion Delaunay,Michael R Bristow,Gregory P Way,Timothy A McKinsey
-
Evolution of TAVR as a Technology: Do Real-World Outcomes Still Support Expanded Use? Circulation (IF 35.5) Pub Date : 2025-04-21 Frederick G P Welt,Jason P Glotzbach
-
Response by Jia et al to Letter Regarding Article, "Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial". Circulation (IF 35.5) Pub Date : 2025-04-21 Ping Jia,Zhe Luo,Xiaoqiang Ding
-
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation (IF 35.5) Pub Date : 2025-04-21 Andre Zimerman,Ana Laura F Kunzler,Brittany N Weber,Xinhui Ran,Sabina A Murphy,Huei Wang,Narimon Honarpour,Anthony C Keech,Peter S Sever,Marc S Sabatine,Robert P Giugliano
BACKGROUND Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but
-
High-Volume Physical Activity and Clinical Coronary Artery Disease Outcomes: Findings From the Cooper Center Longitudinal Study. Circulation (IF 35.5) Pub Date : 2025-04-21 Jarett D Berry,Noor Zabad,Douglas Kyrouac,David Leonard,Carolyn E Barlow,Andjelka Pavlovic,Kerem Shuval,Benjamin D Levine,Laura F DeFina
BACKGROUND High-volume physical activity (PA) is associated with a higher prevalence of subclinical coronary artery disease (CAD). However, the clinical significance of subclinical CAD among high-volume exercisers remains incompletely understood, and the dose-response relationship between high-volume PA and clinical CAD events remains uncertain. METHODS Individual participant data from the Cooper Center
-
Palliative Care and Advanced Cardiovascular Disease in Adults: Not Just End-of-Life Care: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-04-17 Lucinda J Graven,Lisa Kitko,Martha Abshire Saylor,Larry Allen,Angela Durante,Lorraine S Evangelista,Amy Fiedler,James Kirkpatrick,Lakeisha Mixon,Rachel Wells,
Cardiovascular disease remains a leading cause of morbidity and mortality in adults despite recent scientific advancements. Although people are living longer lives, there may be an adverse impact on quality of life, necessitating a greater need for palliative care services and support. Palliative care for adults with advanced cardiovascular disease has the potential to significantly improve quality
-
Risk-Based Primary Prevention of Heart Failure: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-04-16 Sadiya S Khan,Khadijah Breathett,Lynne T Braun,Sheryl L Chow,Deepak K Gupta,Carolyn Lekavich,Donald M Lloyd-Jones,Chiadi E Ndumele,Carlos J Rodriguez,Larry A Allen,
The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice. First, the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of
-
Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality. Circulation (IF 35.5) Pub Date : 2025-04-14 Emmanuel Stamatakis,Raaj K Biswas,Nicholas A Koemel,Angelo Sabag,Richard Pulsford,Andrew J Atkin,Afroditi Stathi,Sonia Cheng,Cecilie Thøgersen-Ntoumani,Joanna M Blodgett,Adrian Bauman,Carlos Celis-Morales,Mark Hamer,Jason M R Gill,Matthew N Ahmadi
BACKGROUND Few middle-aged and older adults engage in regular leisure-time exercise. Incidental physical activity (IPA) encompasses activities of daily living outside the leisure-time domain. No dose-response study is available to guide IPA-focused interventions and guidelines. We examined the associations of device-assessed IPA intensities (vigorous [VIPA], moderate [MIPA], light [LIPA]) with major
-
Reprogrammed Smooth Muscle Cells for Vascular Repair: A New Path to Healing Ischemic Tissue. Circulation (IF 35.5) Pub Date : 2025-04-14 Li Qian
-
Response by Peigh et al to Letter Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices". Circulation (IF 35.5) Pub Date : 2025-04-14 Graham Peigh,Sarah C Rosemas,Anthony I Roberts,Colleen Longacre,Rod S Passman
-
Assessing the Consequences of Retrograde and Transseptal Approaches to Ventricular Arrhythmia Ablation. Circulation (IF 35.5) Pub Date : 2025-04-14 Nikolas Nozica,Usha Tedrow
-
Patient-Reported Outcomes as End Points in Heart Failure Trials. Circulation (IF 35.5) Pub Date : 2025-04-14 Javed Butler,Muhammad Shariq Usman,Charu Gandotra,Ali Salman,Andrew Farb,Aliza M Thompson,Norman Stockbridge,Cordula Zeller,Folke Folkvaljon
Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized. Regulatory agencies consider PROs part of their evaluation of drugs and devices
-
Letter by Lu et al Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices". Circulation (IF 35.5) Pub Date : 2025-04-14 Xiaofeng Lu,Shaowen Liu,Songwen Chen
-
Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation (IF 35.5) Pub Date : 2025-04-11 Yan Zou,Jing Lu,Zhipeng Lian,Jianguo Jia,Juan Shen,Qianhe Li,Jennifer Ming Jen Wong,Kejia Jin,Wendi Yan,Xinyue Ren,Yang Zhang,Chenxing Huang,Huanjie Yang,Feng Huang,Jun Li,Junyu Zhai,Yamei Xu,Xialian Xu,Hang Yu,Yi Jin,Hui Gong,Jinzhong Lin,Junbo Ge,Yuxiang Dai
BACKGROUND Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies
-
Sedentary Behavior and Light-Intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-04-10 Kara M Whitaker,Bethany Barone Gibbs,Marie-France Hivert,Nour Makarem,Elizabeth Moxley,Jason Vaught,Kelly R Evenson,
The Physical Activity Guidelines for Americans supports sitting less and moving more. Growing evidence suggests that a waking behavior profile with less sedentary behavior and more light-intensity physical activity is associated with more favorable cardiovascular health. Remarkably, little is known about how these behaviors relate to cardiovascular health during pregnancy. The purpose of this American
-
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES. Circulation (IF 35.5) Pub Date : 2025-04-07 P Gabriel Steg,Michael Szarek,J Wouter Jukema,Deepak L Bhatt,Vera A Bittner,Rafael Diaz,Sergio Fazio,Geneviève Garon,Shaun G Goodman,Robert A Harrington,Harvey D White,Andreas M Zeiher,Gregory G Schwartz,
-
Natriuretic Peptides for the Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation (IF 35.5) Pub Date : 2025-04-07 Torbjørn Omland,Nicholas L Mills
-
Predicting Cardiovascular Risk With Use of Various Tobacco Products. Circulation (IF 35.5) Pub Date : 2025-04-07 Neal L Benowitz
-
Racial Disparities in Long-Term Outcomes After Endovascular Aortic Aneurysm Repair in Black and White Medicare Beneficiaries. Circulation (IF 35.5) Pub Date : 2025-04-07 Abena Appah-Sampong,Christina Marcaccio,Siling Li,Yang Song,Mohamad A Hussain,Robert Yeh,Marc L Schermerhorn,Eric A Secemsky
BACKGROUND Despite reported racial disparities between Black and White adults in short-term outcomes after abdominal aortic aneurysmal intervention, there is a paucity of literature aimed at understanding long-term disparities. The present study aims to characterize racial disparities in long-term outcomes, perioperative outcomes, and health care use after endovascular aortic aneurysm repair. METHODS
-
Role of Technology in Promoting Heart Healthy Behavior Change to Increase Equity in Optimal Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation (IF 35.5) Pub Date : 2025-04-07 Tiffany M Powell-Wiley,LaPrincess C Brewer,Lora E Burke,Rosalba Hernandez,Jill Landsbaugh Kaar,Maura Kepper,Christopher E Kline,Keila N Lopez,Shamarial Roberson,Colleen K Spees,Gerald J Jerome,
Populations most affected by cardiovascular health disparities, including underrepresented populations with lower socioeconomic status, people with disabilities, and those living in underserved rural communities, are disproportionately exposed to adverse social determinants of health. Specifically, economic instability and suboptimal living conditions within the neighborhood and built environment directly
-
Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry. Circulation (IF 35.5) Pub Date : 2025-04-03 Andrew M Vekstein,Zachary K Wegermann,Pratik Manandhar,Michael J Mack,David J Cohen,G Chad Hughes,J Kevin Harrison,Tsuyoshi Kaneko,Samir R Kapadia,Konstantinos Stathogiannis,William F Fearon,Suzanne Arnold,Andrzej S Kosinski,Martin B Leon,Wayne B Batchelor,Vinod H Thourani,Sreekanth Vemulapalli
BACKGROUND Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption. METHODS We identified heart team-designated low-risk patients undergoing TAVR for trileaflet severe, symptomatic aortic stenosis in the Society of Thoracic
-
Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF. Circulation (IF 35.5) Pub Date : 2025-04-01 Xiong Guo,Chong Huang,Ling Zhang,Guangyu Hu,Yunhui Du,Xiyao Chen,Fangfang Sun,Tongzheng Li,Zhe Cui,Congye Li,Yongzhen Guo,Wenjun Yan,Yunlong Xia,Shan Wang,Hui Liu,Zhiyuan Liu,Zhen Lin,Xinyi Wang,Zhengyang Wang,Fuyang Zhang,Ling Tao
BACKGROUND Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored. METHODS We examined cardiac lymphatic alterations in mice with HFpEF with comorbid
-
Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes. Circulation (IF 35.5) Pub Date : 2025-04-01 Eric J Kort,Nazish Sayed,Chun Liu,Gema Mondéjar-Parreño,Jens Forsberg,Emily Eugster,Sean M Wu,Joseph C Wu,Stefan Jovinge
BACKGROUND Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients. METHODS The National Institutes of Health
-
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure. Circulation (IF 35.5) Pub Date : 2025-04-01 Signe Glargaard,Jakob Hartvig Thomsen,Christian Tuxen,Matias Greve Lindholm,Christian Axel Bang,Morten Schou,Kasper Iversen,Rasmus Vedby Rasmussen,Brian Bridal Løgstrup,Søren Vraa,Nis Stride,Ekim Seven,Anders Barasa,Marlene Tofterup,Dan Eik Høfsten,Kasper Rossing,Lars Køber,Finn Gustafsson,Jens Jakob Thune
BACKGROUND TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion. METHODS This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute